Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Shareholder Meeting (December 2025)
37 slides from Coloplast A/s Class B's shareholder meeting presentation, December 2025
Slide 1: Coloplast Annual General Meeting 2024/25
Coloplast Annual General Meeting 2024/25 Dorte | User, Bowel Care
Slide 2: Chair of the Board
Chair of the Board Jette Nygaard-Andersen 2
Slide 3: Board of Directors: Other shareholder-elected Board members
Board of Directors Other shareholder-elected Board members Annette Brüls Carsten Hellmann Lars Rasmussen Marianne Wiinholt 3
Slide 4: Board of Directors: Employee-elected Board members
Board of Directors Employee-elected Board members Thomas Barfod Roland Vendelbo Pedersen Nikolaj Kyhe Gundersen 4
Slide 5: Executive Leadership Team
Executive Leadership Team Lars Rasmussen Anders Lonning-Skovgaard Dorthe Rønnau Allan Rasmussen Interim CEO EVP, CFO EVP, People & Culture EVP, Operations since 2025 At Coloplast since 2006 At Coloplast since 2022 At Coloplast since 1992 Chronic Care Acute Care Caroline Vagner Rosenstand Rasmus Just
Slide 6: Coloplast Annual General Meeting 2024/25
Coloplast Annual General Meeting 2024/25 Lucie | User, Ostomy Care
Slide 7: Agenda
Agenda 1. The board of directors' report 2. Presentation and approval of the annual report 3. Decision on the use of profit 4. Presentation and approval of the remuneration report 5. Approval of the board’s remuneration 6. Proposals from the board or shareholders 7. Election of members to the board
Slide 8: Agenda
Agenda 1. The board of directors' report 2. Presentation and approval of the annual report 3. Decision on the use of profit 4. Presentation and approval of the remuneration report 5. Approval of the board’s remuneration 6. Proposals from the board or shareholders 7. Election of members to the board
Slide 9: Chair of the Board
Chair of the Board Jette Nygaard-Andersen 9
Slide 10: This year, Coloplast helped more than two million people
This year, Coloplast helped more than two million people with intimate healthcare needs… Martyn | User, Ostomy Care
Slide 11: 2024/25 was a year marked by challenges, but also important decisions
2024/25 was a year marked by challenges, but also by important decisions for Coloplast’s future 7 % 28 %* Organic growth EBIT margin *before special items Stina | User, Continence Care
Slide 12: Strive25 – focus on innovation and growth
Strive25 – focus on innovation and growth Victoria | User, Ostomy Care
Slide 13: Executive Leadership Team
Executive Leadership Team Lars Rasmussen Anders Lonning-Skovgaard Dorthe Rønnau Allan Rasmussen Interim CEO EVP, CFO EVP, People & Culture EVP, Operations since 2025 At Coloplast since 2006 At Coloplast since 2022 At Coloplast since 1992 Chronic Care Acute Care Caroline Vagner Rosenstand Rasmus Just
Slide 14: Impact4
Impact4 Grow through innovative customer offerings Unlock next level efficiency gains ro O J é.. Embrace technology Cultivate a winning to elevate user and sustainable experience and scale company @& Coloplast
Slide 15: Grow through innovative customer offerings
Grow through innovative customer offerings Strengthen the customer experience at all levels - through products, services and partnerships - so Coloplast remains the preferred choice. Chronic Care: Strengthen our market leading position by: Getting closer to our users and elevating the customer exper
Slide 16: Unlock next level efficiency gains
Unlock next level efficiency gains A paradigm shift in ways of working to enhance scalability and efficiency across the company Drive efficiency in Global Operations to offset external headwinds and deliver gross margin accretion Reduce complexity through portfolio simplification Finalise integratio
Slide 17: Embrace technology to elevate user experience and scale
Embrace technology to elevate user experience and scale Step up technology investments to enable a best-in-class customer experience at scale Utilise technology including AI to enhance customer experience Utilise technology including AI to drive efficiency improvements across the business Dedicated
Slide 18: Cultivate a winning and sustainable company
Cultivate a winning and sustainable company Enable strategy execution by shifting our company towards a faster and even more customer-centric organisation Introduction of a new Coloplast leadership program, nurturing a high-performing and customer-centric culture in a large company Develop leadershi
Slide 19: The priorities set in Impact4 will drive long-term value creation
The priorities set in Impact4 will drive compelling long-term value creation 2030 Financial ambition: 1 2 Organic revenue EBIT growth1 in line growth of 7-8% (5- with or above revenue year CAGR) growth over the period 3 Return on Invested Capital of more than 20% in FY 2029/302 1. In constant curren
Slide 20: Impact4
Impact4 Grow through innovative customer offerings Unlock next level efficiency gains ro O J é.. Embrace technology Cultivate a winning to elevate user and sustainable experience and scale company @& Coloplast
Slide 21: Key ratios 2024/25
Key ratios 2024/25 mDKK 2024/25 2023/24 Change Net revenue 27,874 27,030 3% Gross margin 68% 68% - Operating profit 7,670* 7,286* 5% (EBIT) Operating margin 28%* 27%* 1%-point (EBIT margin) ROIC after tax 15%** 15%* - *Before special items **Before special items and adjusted for tax related to the K
Slide 22: Profit 2024/25
Profit 2024/25 Net profit for the year DKK 3,636m Total assets DKK 48,367m Equity DKK 16,122m Free cash flow for the year DKK 5,394m Net interest-bearing debt DKK 21,692m Dividend DKK 23.00 per DKK 5,184m share Pay-out ratio 143% 22 Simone | Ostomy Care
Slide 23: Share price development
Share price development 875 DKK 1000 30 September 2024 950 900 850 800 579 DKK 3 December 2025 750 700 650 600 550 500 1.10.24 1.11.24 1.12.24 1.1.25 1.2.25 1.3.25 1.4.25 1.5.25 1.6.25 1.7.25 1.8.25 1.9.25 1.10.25 1.11.25 1.12.25 23 Coloplast’s share price development in DKK
Slide 24: Financial expectations for 2025/26
Financial expectations for 2025/26 1 2 3 ~7% ~7%* ~16% Organic growth in EBIT growth in Return on constant currencies constant currencies invested capital *before special items
Slide 25: [Vis Impact4 film]
[Vis Impact4 film] © colopiast
Slide 26: Coloplast Annual General Meeting 2024/25
Coloplast Annual General Meeting 2024/25 Lucie | User, Ostomy Care
Slide 27: Agenda
Agenda 1. The board of directors' report 2. Presentation and approval of the annual report 3. Decision on the use of profit 4. Presentation and approval of the remuneration report 5. Approval of the board’s remuneration 6. Proposals from the board or shareholders 7. Election of members to the board
Slide 28: Agenda
Agenda 1. The board of directors' report 2. Presentation and approval of the annual report 3. Decision on the use of profit 4. Presentation and approval of the remuneration report 5. Approval of the board’s remuneration 6. Proposals from the board or shareholders 7. Election of members to the board
Slide 29: 5. Approval of the board's remuneration
5. Approval of the board’s remuneration The Board of Directors proposes that the remuneration for the Board for the financial year 2025/26 be set as follows: • that ordinary members of the Board receive a base fee of DKK 500,000 • that the Deputy Chair of the Board receive a fee of DKK 875,000, equa
Slide 30: Agenda
Agenda 1. The board of directors' report 2. Presentation and approval of the annual report 3. Decision on the use of profit 4. Presentation and approval of the remuneration report 5. Approval of the board’s remuneration 6. Proposals from the board or shareholders 7. Election of members to the board
Slide 31: 6.1 Update of the remuneration policy
6.1 Update of the remuneration policy The Board of Directors proposes that the company’s remuneration policy be amended. The main changes and clarifications are described in more detail in the notice convening the general meeting. An updated draft of the remuneration policy has also been available o
Slide 32: Agenda
Agenda 1. The board of directors' report 2. Presentation and approval of the annual report 3. Decision on the use of profit 4. Presentation and approval of the remuneration report 5. Approval of the board’s remuneration 6. Proposals from the board or shareholders 7. Election of members to the board
Slide 33: 7. Election of members to the Board of Directors
7. Election of members to the Board of Directors Lars Søren Rasmussen has decided not to seek re-election. The following board members are therefore proposed for re-election: • Niels Peter Louis-Hansen • Annette Brüls • Carsten Hellmann • Jette Nygaard-Andersen • Marianne Wiinholt As a new member of
Slide 34: Agenda
Agenda 1. The board of directors' report 2. Presentation and approval of the annual report 3. Decision on the use of profit 4. Presentation and approval of the remuneration report 5. Approval of the board’s remuneration 6. Proposals from the board or shareholders 7. Election of members to the board
Slide 35: Agenda
Agenda 1. The board of directors' report 2. Presentation and approval of the annual report 3. Decision on the use of profit 4. Presentation and approval of the remuneration report 5. Approval of the board’s remuneration 6. Proposals from the board or shareholders 7. Election of members to the board
Slide 36: Agenda
Agenda 1. The board of directors' report 2. Presentation and approval of the annual report 3. Decision on the use of profit 4. Presentation and approval of the remuneration report 5. Approval of the board’s remuneration 6. Proposals from the board or shareholders 7. Election of members to the board
Slide 37: Coloplast
= Coloplast